within Pharmacolibrary.Drugs.C_CardiovascularSystem.C09B_AceInhibitorsCombinations.C09BB07_RamiprilAndAmlodipine;

model RamiprilAndAmlodipine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 1.2499999999999999e-05,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.07,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 900,
    Vdp = 0.12,
    k12 = 2.2222222222222223e-05,
    k21 = 2.2222222222222223e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>RamiprilAndAmlodipine</td></tr><tr><td>ATC code:</td><td>C09BB07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>70</td><td>L</td></tr>
    <tr><td>clearance:</td><td>45</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ramipril is an angiotensin-converting enzyme (ACE) inhibitor and amlodipine is a dihydropyridine calcium channel blocker. This fixed dose combination is used for the treatment of hypertension and/or cardiovascular risk reduction. Both drugs are widely approved and in current clinical use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for orally administered ramipril and amlodipine in adults based on the known PK profiles of each agent in healthy subjects.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C09BB07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end RamiprilAndAmlodipine;
